Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Titel:
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Auteur:
Ramalingam, Suresh S. Pérol, Maurice Reck, Martin Kowalyszyn, Ruben Dario Gautschi, Oliver Kimmich, Martin Cho, Eun Kyung Czyzewicz, Grzegorz Grigorescu, Alexandru Karaseva, Nina Dakhil, Shaker Lee, Pablo Zimmerman, Annamaria Sashegyi, Andreas Alexandris, Ekaterine Carter, Gebra Cuyun Winfree, Katherine B. Garon, Edward B.